|
Health outcome
|
Main source of variation
|
Population at risk
|
Period of exposure measurement
|
n
|
Impact (mean estimate)
|
CI low (€2006)
|
CI mean (€2006)
|
CI high (€2006)
|
Proportion (mean estimate)
|
|---|
|
Liver cancer
|
Conversion from ingestion dose to blood chlordecone
|
All
|
<2003
|
436 968
|
5.4
|
8 821 000
|
13 129 000
|
26 874 000
|
34 %
|
|
≥2003
|
458 465
|
2.0
|
3 274 000
|
4 873 000
|
9 974 000
|
21 %
|
|
Annual benefit
| |
−3.4
|
5 547 000
|
8 256 000
|
16 900 000
|
56 %
|
|
Prostate cancer
|
IC95% of RR
|
Men > 44 years
|
<2003
|
72 566
|
2.8
|
1 405 000
|
5 152 000
|
10 572 000
|
13 %
|
|
≥2003
|
76 049
|
1.0
|
490 000
|
1 797 000
|
3 687 000
|
8 %
|
|
Annual benefit
| |
−1.8
|
915 000
|
3 355 000
|
6 885 000
|
23 %
|
|
Renal dysfunction
|
BMD10-HED
|
Women
|
<2003
|
227 417
|
0.10
|
27 000
|
308 000
|
769 000
|
0.80 %
|
|
≥2003
|
239 470
|
0.04
|
11 000
|
128 000
|
320 000
|
0.54 %
|
|
Annual benefit
| |
−0.06
|
16 000
|
180 000
|
449 000
|
1.23 %
|
|
Cognitive development
|
Equivalence between QI point and ASQ point
|
Male new born
|
<2003
|
3 747
|
1 173
|
3 949 000
|
19 745 000
|
39 489 000
|
52 %
|
|
≥2003
|
3 929
|
1 003
|
3 377 000
|
16 887 000
|
33 773 000
|
71 %
|
|
Annual benefit
| |
−168
|
572 000
|
2 858 000
|
5 716 000
|
20 %
|
|
Total
| | |
<2003
| | |
14 202 000
|
38 334 000
|
77 704 000
|
100 %
|
|
≥2003
| | |
7 152 000
|
23 685 000
|
47 754 000
|
100 %
|
|
Annual benefit
| | |
7 050 000
|
14 649 000
|
29 950 000
|
100 %
|
-
n = population, 2002 census data for the first period of time and 2006 census data for second period. Impacts are expressed in number of death, except for cognitive development where the impacts are expressed in QI point lost. CI = Cost of Impacts (= DALY * VOLY)
- Impact is the number of cases (Eq.3), except IQ points for Cognitive development
